Skip to content
Open access

The APOL1 protective M1 modifier occurs exclusively with the KIK protein haplotype to suppress channel conductance

Sep 2026 · medRxiv · 0 citations
Medicine

TL;DR

Two large community datasets were analyzed to determine if M1 occurs on other APOL1 protein haplotypes and used a cell model to assess if the M1 variant alone is sufficient to block channel activity or if its haplotype context modifies its function.

Read PDF

Similar papers

Open access Sep 2026

Coding, modifier, and regulatory effects shape circulating APOL1 levels

Abstract APOL1 variants G1 and G2 are major genetic risk factors for chronic kidney disease in people with recent sub-Saharan African ancestry, yet the mechanisms linking genotype to disease remain poorly defined. Circulating APOL1 is likely to play a critical role, although how specific genotypes and regulatory varian...

W. Adamson, H. Noyes, J. Ogunsola et al. · 0 citations
Open access Oct 2026

GCH1 p.Ser80Asn Confers Risk for Parkinson's Disease in East Asian Populations.

INTRODUCTION GCH1 has been implicated in Parkinson's disease (PD), but its risks variants and associations are not well defined. OBJECTIVES Our goal was to investigate the clinical relevance and PD risk associated with the GCH1 p.Ser80Asn variant. METHODS We first identified a segregating GCH1 p.Ser80Asn variant in...

Yi-Wen Tay, A. Lee, J. Schee et al. · 0 citations
Review Open access Oct 2026

TMEM106B risk converges on C-terminal fragment homeostasis: genetics, mechanisms and therapy.

Evidence on the roles of TMEM106B within the endo-lysosomal system and beyond is integrated, including insights into protein structure, posttranslational modifications, interactors, proteolytic processing, and fibril formation.

Miranda Lastra Osua, Jolien Perneel, Cristina T. Vicente et al. · 0 citations
Oct 2026

Distribution of the J1 haplotype variant rs2267439 across CYP2D6 diplotypes and its impact on risperidone metabolism.

CYP2D6 is a highly polymorphic pharmacogene responsible for the metabolism of more than 20% of commonly prescribed drugs. Clinical implementation of CYP2D6 pharmacogenetics relies on star allele nomenclature and the Activity Score system, yet substantial interindividual variability in drug exposure remains unexplained....

Antonio Asensi-Cantó, Wendy Y. Wang, Erin C. Boone et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.